The Boston Globe (4/10, Weisman) reports critics warn that the Food and Drug Administration “may sacrifice patient safety” in an effort to accelerate drug approvals. Public Citizen’s health research director Michael Carome says the process is “already too fast,” and believes that the agency can’t “make it any faster without compromising public health.” Others say there is “no evidence the FDA is a bottleneck,” and call the efforts “wrongheaded.”
Related Links:
— “Critics worry faster FDA drug reviews could compromise safety,” Robert Weisman, Boston Globe, April 10, 2017.